Cellebrite DI (NASDAQ:CLBT) reported first-quarter 2026 results that management said met or exceeded the high end of its guidance for annual recurring revenue and adjusted EBITDA, while executives highlighted a wave of new product launches centered on artificial intelligence, cloud-based case management and mobile device access.
Chief Executive Officer Tom Hogan said ARR rose 21% year-over-year to $493 million, while adjusted EBITDA increased 29% to $30.6 million. The company’s trailing 12-month free cash flow margin was 32%, and Hogan said Cellebrite’s “rule of x” continued to track above 50.
